Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X about an article he and his colleagues authored:
“Lots of activity in the KRAS targeting space but always a pleasure to hear Valerie LeBleu talk about MD Anderson Cancer Center “farm to table” in-house iExosome effort, sans ANY toxicity in patients and with great target engagement data. Read the phase 1 paper here.”
Title: Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Authors: Valerie S. Kalluri, Brandon G. Smaglo, Krishnan K. Mahadevan, Michelle L. Kirtley, Kathleen M. McAndrews, Mayela Mendt, Sujuan Yang, Ana S. Maldonado, Hikaru Sugimoto, Maria E. Salvatierra, Luisa M. Solis Soto, Cara Haymaker, Rick Finch, Mihai Gagea, Adam C. Fluty, Steven J. Ludtke, J. Jack Lee, Abhinav K. Jain, Gauri Varadhachary, Rachna T. Shroff, Anirban Maitra, Elizabeth Shpall, Shubham Pant, Raghu Kalluri
More posts featuring Anirban Maitra on OncoDaily.